Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:MNOV - MediciNova Stock Price, Forecast & News

$6.54
-0.17 (-2.53 %)
(As of 01/23/2020 08:48 AM ET)
Add
Compare
Today's Range
$6.51
Now: $6.54▼
$6.67
50-Day Range
$6.45
MA: $7.07▼
$7.99
52-Week Range
$6.36
Now: $6.54▼
$13.37
Volume48,457 shs
Average Volume66,905 shs
Market Capitalization$286.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.16
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
Previous Symbol
CUSIPN/A
CIK1226616
Webhttp://medicinova.com/
Phone858-373-1500

Debt

Debt-to-Equity RatioN/A
Current Ratio36.49
Quick Ratio36.49

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.75 per share
Price / Book3.74

Profitability

EPS (Most Recent Fiscal Year)($0.36)
Net Income$-14,670,000.00
Net MarginsN/A
Return on Equity-15.11%
Return on Assets-14.35%

Miscellaneous

Employees9
Outstanding Shares43,840,000
Market Cap$286.71 million
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:MNOV Rates by TradingView

(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

MediciNova (NASDAQ:MNOV) Frequently Asked Questions

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Friday, October, 25th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.10. View MediciNova's Earnings History.

When is MediciNova's next earnings date?

MediciNova is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for MediciNova.

What price target have analysts set for MNOV?

1 brokers have issued twelve-month price targets for MediciNova's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate MediciNova's share price to reach $22.00 in the next year. This suggests a possible upside of 236.4% from the stock's current price. View Analyst Price Targets for MediciNova.

What is the consensus analysts' recommendation for MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.

Has MediciNova been receiving favorable news coverage?

News headlines about MNOV stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MediciNova earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for MediciNova.

Are investors shorting MediciNova?

MediciNova saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 2,940,000 shares, a drop of 8.1% from the December 15th total of 3,200,000 shares. Based on an average daily volume of 108,000 shares, the days-to-cover ratio is presently 27.2 days. Approximately 8.0% of the shares of the stock are sold short. View MediciNova's Current Options Chain.

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

Who are MediciNova's key executives?

MediciNova's management team includes the folowing people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
  • Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
  • Ms. Carla Reyes, Chief Financial Officer (Age 47)
  • Mr. John O'Neil CPA, Controller

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Alpine Global Management LLC (0.03%). View Institutional Ownership Trends for MediciNova.

Which institutional investors are buying MediciNova stock?

MNOV stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. View Insider Buying and Selling for MediciNova.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $6.54.

How big of a company is MediciNova?

MediciNova has a market capitalization of $286.71 million. The biopharmaceutical company earns $-14,670,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe.View Additional Information About MediciNova.

What is MediciNova's official website?

The official website for MediciNova is http://medicinova.com/.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


MarketBeat Community Rating for MediciNova (NASDAQ MNOV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: How to invest using market indexes
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel